December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Biocompatibility of a Neurotransmitter Based Retinal and Cortical Visual Prosthesis
Author Affiliations & Notes
  • TL Walraven
    Kresge Eye Institute Ligon Research Center of Vision Wayne State University Detroit MI
    Ophthalmology
  • R Iezzi
    Kresge Eye Institute Ligon Research Center of Vision Wayne State University Detroit MI
    Ophthalmology
  • JP McAllister
    Neurosurgery
    Kresge Eye Institute Ligon Research Center of Vision Wayne State University Detroit MI
  • G Auner
    Electrical & Computer Engineering
    Kresge Eye Institute Ligon Research Center of Vision Wayne State University Detroit MI
  • R Givens
    Chemistry University of Kansas Lawrence KS
  • G Abrams
    Kresge Eye Institute Ligon Research Center of Vision Wayne State University Detroit MI
    Ophthalmology
  • Footnotes
    Commercial Relationships   T.L. Walraven, None; R. Iezzi, None; J.P. McAllister, None; G. Auner, None; R. Givens, None; G. Abrams, None. Grant Identification: Ligon Research Fund, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4453. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      TL Walraven, R Iezzi, JP McAllister, G Auner, R Givens, G Abrams; Biocompatibility of a Neurotransmitter Based Retinal and Cortical Visual Prosthesis . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4453.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To assess the biocompatibility of a phototriggerable, caged molecule that could be used in a neurotransmitter-based retinal visual prosthetic device. Methods: Visual cortical neurons were cultured from 19-day old embryonic Sprague-Dawley rat pups and plated onto poly-d-lysine coated glass coverslips. Cultures were incubated for 8 days before exposure to either L-glutamate [20, 35 or 50 uM] or p-Hydroxyphenacyl (HPA) glutamate [20, 35 or 50 uM]. Cellular viability and DNA fragmentation were assessed both 6 and 24 hours after the initial exposure using trypan blue dye exclusion assay and TUNEL staining. Results: While L-glutamate demonstrates excitotoxicity to our cultures in a dose-dependent manner, the HPA glutamate treated cells demonstrated a lower rate of DNA fragmentation and a higher rate of cellular viability (see table - data represents mean and standard deviation). Conclusions: De-activation of L-glutamate with the phototriggerable HPA cage greatly attenuates dose-dependent, excitotoxic effects to our cultures. This improved biocompatibility may render HPA glutamate an important component in a neurotransmitter based visual prosthesis.  

Keywords: 490 neurotransmitters/neurotransmitter systems • 390 drug toxicity/drug effects • 402 excitatory neurotransmitters 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×